Securities and Exchange Commission

Washington, D.C. 20549

 

 

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.  )*

 

 

AN2 Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

037326105

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 037326105   Schedule 13G   Page 1 of 5

 

 1   

 Names of Reporting Persons

 

 Eric Easom

 2  

 Check the Appropriate Box if a Member of a Group

 

 (a) ☐  (b) ☐

 3  

 SEC Use Only

 

 4  

 Citizenship or Place of Organization

 

 United States

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

   5   

 Sole Voting Power

 

 1,572,170

   6  

 Shared Voting Power

 

 0

   7  

 Sole Dispositive Power

 

 1,572,170

   8  

 Shared Dispositive Power

 

 0

 9   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 1,572,170

10  

 Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 Not Applicable

11  

 Percent of Class Represented by Amount in Row 9

 

 5.2%

12  

 Type of Reporting Person

 

 IN


CUSIP No. 037326105   Schedule 13G   Page 2 of 5

 

ITEM 1.

(a) Name of Issuer:

AN2 Therapeutics, Inc. (the “Issuer”).

 

  (b)

Address of Issuer’s Principal Executive Offices:

1800 El Camino Real, Suite D, Menlo Park, CA 94027

 

ITEM 2.

(a) Name of Person Filing:

This statement is filed on behalf of Eric Easom (the “Reporting Person”).

 

  (b)

Address or Principal Business Office:

The business address of the Reporting Person is c/o AN2 Therapeutics, Inc., 1800 El Camino Real, Suite D, Menlo Park, CA 94027.

 

  (c)

Citizenship of each Reporting Person is:

The Reporting Person is a citizen of the United States.

 

  (d)

Title of Class of Securities:

Common Stock, par value $0.00001 per share (“Common Stock”).

 

  (e)

CUSIP Number:

037326105

 

ITEM 3.

Not applicable.


CUSIP No. 037326105   Schedule 13G   Page 3 of 5

 

ITEM 4.

Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2023, based upon 29,741,445 shares of Common Stock outstanding as of November 2, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

 

Reporting Person   

Amount

beneficially

owned

    

Percent

of class:

    Sole power
to vote or
to direct
the vote:
     Shared power
to vote or to
direct the vote:
    

Sole
power to
dispose or
to direct
the
disposition

of:

    

Shared

power to

dispose or

to direct

the

disposition

of:

 

Eric Easom

     1,572,170        5.2     1,572,170        0        1,572,170        0  

The Reporting Person is the beneficial owner of 1,572,170 shares of Common Stock, which consists of (i) 4,907 shares of Common Stock held directly by the Reporting Person, (ii) 1,209,882 shares of Common Stock held by various family trusts, over which the Reporting Person serves as trustee, and (iii) 357,381 shares of Common Stock underlying stock options that are vested or will vest within 60 days of December 31, 2023.

 

ITEM 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

 

ITEM 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

ITEM 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

 

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.

 

ITEM 9.

Notice of Dissolution of Group.

Not applicable.


CUSIP No. 037326105   Schedule 13G   Page 4 of 5

 

ITEM 10.

Certification.

Not applicable.


CUSIP No. 037326105   Schedule 13G   Page 5 of 5

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2024

 

Eric Easom

 

/s/ Eric Easom


AN2 Therapeutics (NASDAQ:ANTX)
過去 株価チャート
から 3 2024 まで 4 2024 AN2 Therapeuticsのチャートをもっと見るにはこちらをクリック
AN2 Therapeutics (NASDAQ:ANTX)
過去 株価チャート
から 4 2023 まで 4 2024 AN2 Therapeuticsのチャートをもっと見るにはこちらをクリック